Find policies, billing codes, payers, states, and providers
Loading...
Create a personalized view of the payer policy updates that matter to you and get notified when changes occur.
Start getting alertsCreate a personalized view of the payer policy updates that matter to you and get notified when changes occur.
Start getting alertsFind policies, billing codes, payers, states, and providers
CPT 87900: Viral Drug Susceptibility Testing, Genotype-to-Phenotype Prediction
CPT-87901-HIV-1-GENOTYPE-REVERSE-TRANSCRIPTASE-PROTEASE-ANALYSISCPT 87901: HIV-1 Genotype Analysis of Reverse Transcriptase and Protease
CPT-87902-HEPATITIS-C-GENOTYPE-NUCLEIC-ACID-TESTING-TECHNICALCPT 87902: Hepatitis C Genotype by Nucleic Acid, Technical Component
CPT-87903-HIV-1-DRUG-RESISTANCE-NUCLEIC-ACID-ANALYSISCPT 87903: HIV-1 Drug Resistance Nucleic Acid Analysis
CPT-87904-HIV-1-DRUG-RESISTANCE-ADDITIONAL-DRUG-TESTINGCPT 87904: HIV-1 Drug Resistance Analysis, Additional Drug
CPT-87905-ENZYMATIC-ACTIVITY-TESTING-INFECTIOUS-AGENT-TECHNICALCPT 87905: Enzymatic Activity Testing for Nonviral Infectious Agents
CPT-87906-HIV-1-GENOTYPE-NUCLEIC-ACID-NON-RT-PROTEASE-REGIONSCPT 87906: HIV-1 Genotype by Nucleic Acid (Non-RT/Protease Regions)
CPT-87910-CMV-GENOTYPE-NUCLEIC-ACID-ANALYSISCPT 87910: CMV Genotype Analysis by Nucleic Acid
CPT-87912-HEPATITIS-B-GENOTYPE-ANALYSIS-NUCLEIC-ACIDCPT 87912: Hepatitis B Virus Genotype Analysis, Nucleic Acid
CPT-87913-SARS-COV-2-GENOTYPE-ANALYSIS-NEXT-GENERATION-SEQUENCINGCPT 87913: SARS–CoV–2 Genotype Analysis by Next-Generation Sequencing
Showing 1–10 of 11
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.